Dianthus Therapeutics
DNTH
74 hedge funds and large institutions have $437M invested in Dianthus Therapeutics in 2019 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 19 increasing their positions, 18 reducing their positions, and 10 closing their positions.
162% more capital inflows, than outflows
Capital inflows: $15.6M | Capital outflows: $5.95M
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
50% more call options, than puts
Call options by funds: $3K | Put options by funds: $2K
3% more funds holding
Funds holding: 72 → 74 (+2)
1.58% more ownership
Funds ownership: 72.4% → 73.98% (+1.6%)
6% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 18
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Eventide Asset Management
Boston,
Massachusetts
|
+$5.12M |
| 2 |
Marshall Wace North America
New York
|
+$1.5M |
| 3 |
Millennium Management
New York
|
+$1.46M |
| 4 |
Alkeon Capital Management
New York
|
+$1.17M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$758K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.08M |
| 2 |
Laurion Capital Management
New York
|
-$987K |
| 3 |
ALPS Advisors
Denver,
Colorado
|
-$793K |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$636K |
| 5 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$505K |
DNTH Hedge Fund Activity: Q4 2019 in Review
74 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q4 2019, worth a combined $437M — up 52% from $288M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new DNTH positions and 10 closed out — a net gain of 7 holders — while 19 added to existing stakes and 18 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $5.12M. The largest seller was Citadel Advisors, cutting an estimated $1.08M.
- 74 institutional investors held Dianthus Therapeutics (DNTH) as of Q4 2019, up from 72 in Q3 2019.
- Funds reported $437M of Dianthus Therapeutics stock for Q4 2019, up 52% quarter-over-quarter.
- 17 funds opened new Dianthus Therapeutics positions in Q4 2019 and 10 closed out, a net change of +7 holders.
- The largest Dianthus Therapeutics buyer in Q4 2019 was Eventide Asset Management, an estimated $5.12M added.
- The largest Dianthus Therapeutics seller in Q4 2019 was Citadel Advisors, an estimated $1.08M sold.
Based on aggregated 13F filings for Q4 2019.